Graham Dark

TL;DR: Vascular shutdown, within experimental and human breast cancer models in vivo following systemic drug administration, was demonstrated with a reduction in functional vascular volume of 93% at 6 h following drug administration and persisted over the next 12 h, with corresponding histology consistent with hemorrhagic necrosis resulting from vascular damage.

TL;DR: A simple taxonomy and nomenclature is proposed in anticipation that the therapeutic potential of this novel class of vascular-targeted therapies can be realized as these approaches advance in clinical settings and a new anticancer strategy becomes available in the clinic.

TL;DR: VRL oral was developed as a line extension of VRL IV on the basis that similar AUCs result in similar activities, and bioequivalence tests were performed to support this calculation.

TL;DR: Efficacy measures for both regimens seem similar to the most effective chemotherapies for advanced non-small cell lung cancer (platinum combinations) with less hematologic and nonhematologic toxicity.

TL;DR: Weekly dose-dense chemotherapy can be delivered successfully as first-line treatment for epithelial ovarian cancer but does not significantly improve progression-free survival compared with standard 3-weekly chemotherapy in predominantly European populations.